Overview of KRAS-Driven Genetically Engineered Mouse Models of Non-Small Cell Lung Cancer.
KRAS, the most frequently mutated oncogene in non-small cell lung cancer, has been utilized extensively to model human lung adenocarcinomas. The results from such studies have enhanced considerably an understanding of the relationship between KRAS and the development of lung cancer. Detailed in this overview are the features of various KRAS-driven genetically engineered mouse models (GEMMs) of non-small cell lung cancer, their utilization, and the potential of these models for the study of lung cancer biology.
Signal Transduction Laboratory, The Francis Crick Institute, London, United Kingdom.
Clare
C
Sheridan
Signal Transduction Laboratory, The Francis Crick Institute, London, United Kingdom.|Lung Cancer Group, The Institute of Cancer Research, London, United Kingdom.
Julian
J
Downward
D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D004195:Disease Models, Animal; D005818:Genetic Engineering / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D051379:Mice; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D019076:Transgenes / Q000235:genetics
C495971:Hras protein, mouse; D016283:Proto-Oncogene Proteins p21(ras)
KRAS; lung cancer; mouse models; non-small cell lung cancer; p53